How Does AI-Assisted Invention Patentability Work Under New USPTO Guidance?

USPTO Inventorship Guidance Explained

Under the new USPTO guidance, AI-assisted inventions remain patentable, but the bar for inventorship hinges on significant human contribution. The key principle is that AI systems cannot be named as inventors because they are not natural persons. Instead, at least one human must have made a significant contribution to the invention's conception. This means simply prompting an AI tool or recognizing its output is generally insufficient. The guidance applies the longstanding "significant contribution" test to each claim, asking whether a human provided a substantial contribution beyond what the AI generated.

Also worth reading: Is an AI Invention Patentable in 2026, and How Should You Navigate an AI Patentability Review? · Who Qualifies as an Inventor in an AI-Assisted Patent Invention? · How Is AI Patent Inventorship Guidance Evolving After USPTO Updates?

For inventors and companies, this creates a practical framework: document human ingenuity carefully. If a human identifies a problem, designs experiments, or refines AI outputs into a patentable invention, that person likely qualifies as an inventor. However, if the AI independently generated the key inventive concept and the human only reduced it to practice, patentability may fail. The guidance also warns against using AI as a mere substitute for human inventorship. Ultimately, patent strategy must now balance AI's speed with clear evidence of human creative input, or risk invalid claims.

Human Contribution Requirements for AI Patents

Under new USPTO guidance, AI-assisted inventions remain patentable, but the human contribution must be significant. The core rule is that inventorship cannot be granted to an AI system; only natural persons can be named as inventors. For an AI-assisted invention to qualify, at least one human must have contributed meaningfully to the conception of the claimed invention. The USPTO applies a "significant contribution" standard, asking whether the human's input was essential to the invention's creation, not merely aiding or executing AI output.

This means inventors must document how they directed, modified, or built upon AI-generated results in a way that rises to the level of conception. Simply prompting an AI and receiving a useful result is unlikely to suffice. The guidance emphasizes that human ingenuity must remain central, even when AI tools accelerate discovery. For patent and trade secret strategy, this creates a critical choice: patent protection requires disclosing human contributions, while trade secrets may avoid that scrutiny but offer weaker exclusivity. Boards and CEOs should ensure their IP policies capture human inventive steps clearly, because failing to meet the USPTO's human contribution requirement can invalidate a patent.

Patents Versus Trade Secrets for AI

Under new USPTO guidance, AI-assisted inventions remain patentable only if a human inventor made a significant contribution to the claimed invention. The key inquiry is whether a natural person provided the inventive concept, not whether AI merely assisted in reducing it to practice. Each claim must be analyzed individually, and inventorship cannot be assigned to an AI system. If a human merely presents an AI's output as their own creation, that claim likely fails the significant contribution test.

This human-centered standard pushes many companies toward trade secret protection instead. Because AI-generated discoveries can be difficult to attribute to a specific human contributor, patent applications risk invalidity for improper inventorship. Trade secrets avoid that disclosure and attribution problem entirely, provided the invention stays secret and reasonable protections exist. However, trade secrets offer no protection against independent discovery or reverse engineering. The strategic choice therefore hinges on whether a defensible human inventive contribution can be documented and whether public disclosure through a patent is worth the risk.

AI Drug Discovery Patent Strategies

Under recent USPTO guidance, AI-assisted inventions are not categorically unpatentable, but patentability depends on human inventorship. An AI system cannot be named as an inventor. Instead, at least one natural person must have made a significant contribution to the conception of the claimed invention. For AI drug discovery, that means documenting how researchers framed the problem, selected training data, designed experiments, interpreted AI outputs, and refined candidates. Merely recognizing an AI-generated output as useful is usually insufficient. The guidance applies existing law, including the Pannu factors, to determine whether each human contributed significantly.

For strategy, applicants should build a provenance record linking human decisions to key claim elements. Claims focused on AI-assisted compounds, targets, biomarkers, or methods should emphasize human-designed experimental validation and optimization. If inventorship is uncertain, trade secret protection may complement patents, especially for models and data pipelines. USPTO inventorship updates and court decisions continue to shape this area, so patent and trade secret strategies should be coordinated early. AI Patent Review at patentreviewpro.com helps innovators assess these risks.

Practical Steps for AI Inventors

Under the USPTO's February 2024 guidance, AI-assisted inventions remain patentable so long as a natural person qualifies as a true inventor under 35 U.S.C. § 100(f). The guidance makes clear that using an AI system as a tool does not disqualify an invention, but the patent application must demonstrate significant human contribution. Examiners apply the Pannu factors, assessing whether each named inventor made a meaningful contribution to the conception of the claimed invention. Practical steps for applicants include documenting how humans directed the AI system, designed the problem, selected and refined outputs, and performed experiments validating results. Simply prompting an AI system with a broad goal and accepting its output is unlikely to establish inventorship, whereas substantially modifying, combining, or building upon AI-generated results with human insight generally will.

For companies navigating AI drug discovery and other research-intensive fields, the guidance intersects with broader intellectual property strategy. Boards should evaluate whether inventions are better protected as trade secrets, particularly where AI-generated innovations may not meet inventorship requirements or where disclosure through patenting would reveal valuable methods. Careful recordkeeping of human contributions, thoughtful inventor designation, and coordinated patent-versus-trade-secret decisions are now essential components of AI innovation management.

Patents vs. Trade Secrets for AI-Assisted Inventions

Under new USPTO guidance, AI-assisted inventions remain patentable only when a natural person significantly contributes to the conception. Because AI cannot be named an inventor, applicants must document human ingenuity carefully. Trade secrets offer an alternative without inventorship hurdles, but reverse engineering and independent discovery pose real risks. Strategy should match the invention’s detectability and business context.